key: cord-0326225-ip2cja32
authors: ten Have, P.; van Hal, P.; Wichers, I.; Kooistra, J.; Hagedoorn, P.; Chavannes, N.; Brakema, E.; de Heer, P.; Ossebaard, H. C.
title: Turning green: the impact of changing to more eco-friendly respiratory healthcare. A carbon and cost analysis of Dutch prescription data.
date: 2021-11-21
journal: nan
DOI: 10.1101/2021.11.20.21266571
sha: f0273a8ceb1b681106148773c32e6ecca6455b2e
doc_id: 326225
cord_uid: ip2cja32

Objectives Dry powder inhalers (DPIs) have a substantially lower global warming potential than pressurized metered-dose inhalers (MDIs). To help mitigate climate change, we assessed the potential reduction in CO2-equivalents when replacing MDIs by DPIs in the Netherlands, and estimated the associated cost. Design We performed a four-step analysis based on data from two national databases of two independent governmental bodies (Dutch National Healthcare Institute and the Dutch Healthcare Authority). First, we calculated the number of patients with Chronic Obstructive Pulmonary Disease (COPD) and asthma that were using inhalation medication (2020). Second, we calculated the number and total of daily defined doses of MDIs, DPIs, and soft mist inhalers and the number of spacers per patients, dispensed by non-hospital based pharmacies in 2020. Third, we estimated the potential reduction in CO2-equivalents (eq.) if all eligible patients ([≥]7 years old; COPD with [≤]exacerbation per year) would switch from using MDIs to using DPIs as eco-friendly alternatives. Fourth, we performed a cost-effectiveness analysis. Results In 2020, 1.4 million patients used inhalers for COPD or asthma treatment. A total of 460 million defined daily doses (DDDs) from inhalers were dispensed, of which, after the exclusion of nebulisers, 50.4% were from MDIs. We estimated that this use could be reduced by 70% leading to annual reduction in emissions of 77 - 84 million kg CO2eq. saving at best EUR 49.8 million annually. Conclusions In the Netherlands, substitution of MDIs to DPIs for eligible patients is theoretically safe and in accordance with medical guidelines, while reducing emissions by 80 million kg.CO2eq. on average and saving at best EUR 49.8 million per year. This study confirms the potential climate and economic benefit of delivering eco-friendlier respiratory care.

 Given availability and reliability of the data, the present analysis can easily be replicated elsewhere which allows for international comparison and aggregation.

 Implementation challenges remain underexposed.

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint

Climate change is the greatest global health threat of this century, inflicting a range of ill health outcomes including (re-)emerging zoonoses such as Covid-19, non-communicable diseases and mental health disorders. [1, 2] Paradoxically, the health care industry contributes substantially to global warming. If global health care were a country, it would rank fifth for greenhouse gas emissions and its environmental footprint is substantial. [3, 4] In the Netherlands, the healthcare sector is responsible for 6-7% of the total national CO2-eq. emission.

[5] Hence, the Dutch healthcare sector could play a significant role in meeting the national climate policy goals, thereby preserving planetary health and population health that depends on it.

Among the impactful solutions to deliver more sustainable healthcare is the choice of inhaler type to deliver medication to the lungs of patients with asthma, allergies, or chronic obstructive pulmonary disease (COPD). Pressurized metered-dose inhalers (MDIs) contain propellants known as hydrofluorocarbons (HFCs), potent F-gases that account for 15 megaton CO2-eq. The global warming potential is the heat absorbed by any greenhouse gas in the atmosphere compared to the mass of CO2. The GWP of CO2 is 1.0. The GWPs of HFC-134a and HFC-227ea, hydrofluorocarbons used in metered dose inhalers, are 1,330 and 3,220.

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint guidelines 'Asthma in adults' [11] and 'COPD' [12] of the Dutch College of General Practitioners.

Among other updates, these guidelines contain the same modest, though historical, reference to considering the environmental impact of the medicine of choice for the prescribing physician (see Box 2) .

To understand the implications of changing from MDI to DPI-use for policy, practice, and patients in another setting, we build on the cost and carbon analysis of Wilkinson et al. [8] . In this paper, we calculated the environmental impact of changing use of MDIs to more ecofriendly DPIs in Dutch primary and secondary respiratory healthcare and analysed the associated pharmaceutical costs.

We performed a four-step data analysis of prescription data in order to estimate the carbon equivalent footprint of prescribed inhalers over a one-year period (2020). We determined how much inhalation medication could be attributed to the following patient groups: 1) asthma, 2) COPD, 3) severe COPD and 4) children younger than 7 years of age. Estimations were based One of the criteria in de decision aide for choosing an inhaler device "A general objection against metered dose inhalers is that they contain a greenhouse gas with a strong environmental impact."

Note "Metered dose inhalers use HFC propellants. The F-gas hydrofluorcarbon does not affect the ozon layer but is a strong greenhouse gas. The environmental impact of 1 inhalation is 25 times larger than a dry-powder inhalation. Environmental impact of production, transport and waste processing (..) have not been included."

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint Supplementary File contains the complete data analysis protocol and additional information regarding methodological details, assumptions and choices made.

First, we calculated the number of patients with asthma or COPD that used inhalation medication in the Netherlands in 2020 by joining diagnoses codes to inhalation medication.

Second, we calculated the number of defined daily doses (DDDs) discriminating between MDIs and DPIs. Nebulisers were excluded from the analysis since they do not contain propellants and due to their size and dependency on electricity, they are not to be considered an alternative to MDIs for use by patients at home. We included the soft mist inhalers in de DPI group, because they don't contain propellants and may be an alternative to MDIs. Third, we determined the volume of MDIs that could hypothetically be replaced by DPIs in a safe and medically responsible way. We estimated the size of this volume in DDDs, according to current medical guidelines excluding children younger than 7 years of age and those patients with severe COPD having at least two exacerbations per year. In our data the subgroups 'younger than 7 years' and 'severe COPD' consume 14.3% of the total medication delivered by MDI.

Hence, if we would disregard their MDI-use, and only replace inhalers of the remaining patients, we could theoretically achieve a 85.7% reduction of MDI-use. In these two subgroups (younger than 7, severe COPD), it is possible to safely replace MDIs in inhalation corticosteroid (ICS) maintenance therapy for DPIs, without any negative medical impact. Here, breathing is not hampered during maintenance therapy and an immediate effect of ICS is not required. We nonetheless choose a more conservative estimate of change. We used the frequently stated figure of 10% MDI-use in Sweden as a proxy assuming Sweden and The Netherlands are comparable in terms of a variety of social-epidemiological indicators. [15, 16] Hence it is likely that the latter country could approach Sweden's level of DPI-prescription to an again more conservative, putative 15%. From the current level of 50.4% down to 15% MDI-use equals a 70% reduction, which is considerably less than the previous 85.7%. Based on our data we know how many canisters of each type were prescribed in 2020, and we applied two conversion Finally we calculated the kg CO2-eq. decrease as a consequence of this substantial 70% reduction in MDI-use. In the fourth and last step we calculated if this potential replacement could be achieved in a cost-neutral way. By determining both the current costs of medication, spacers and estimated replacement costs we calculated the difference. For the replacement costs we applied two realistic scenarios, one is the low-cost scenario in which MDIs are replaced by low-cost DPIs. In the second scenario MDIs are replaced by average-cost DPIs. People living with COPD or asthma were not involved in the design and conduct of this study. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint

In 2020, 1,392,743 patients used inhalation medication in the Netherlands, and they received a total of 459,621,151 defined daily doses (Table 1 ). In addition 549,224 spacers were administered to 509,650 (MDI-using) patients meaning that 61% of 831,494 MDI-using patients could use their inhaler together with a yearly to-be-replaced spacer, as recommended by Dutch medical guidelines. After excluding the use of nebulisers, we focused on the group of 1,388,255 patients using MDI and/or DPI, who were prescribed over 452,689,914 DDDs in 2020 ( Table 1 ).

The total amount of medication delivered in 2020 by MDI is 228,074,487 DDDs. We observed that 50.4% of the medication has been delivered using MDIs, 49.6% per DPIs (Table 1) .

Not all inhalation medication is delivered by both types of inhalers and can be switched. Longacting muscarinic-antagonists (LAMA) and the combination of long-acting beta agonists with long-acting muscarinic-antagonists (LABA-LAMA) were only available as DPI, the combination of short-acting beta agonists with short-acting muscarinic-antagonists (SABA-SAMA) was only available as MDI.

The number of patients that could hypothetically switch safely to DPIs with the same content would be using 154,647,286 DDDs, equal to 4,500,234 canisters. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure 1 ). We calculated if shifting to DPIs could be achieved in a cost-neutral way. We determined both the current costs of medication and spacers, we estimated replacement costs and we calculated the difference. For the replacement costs we applied two realistic scenarios, one is a low-cost scenario in which MDIs are replaced by low-cost DPIs. In the second scenario MDIs are replaced by average-cost DPIs in current market share (Table 2 ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Our results show that a sizeable reduction in greenhouse gas emissions is attainable in the Netherlands with a readily available eco-friendly alternative. The financial impact of this shift depends on the choice for either a low-cost option or a more expensive option, but we demonstrated a cost reduction is feasible if done right. The estimated cost-saving does not include financial calculations of patient training or potential drawbacks of substitution such as lower adherence leading to increased GP visits or hospital admissions.

These results are in accordance with earlier studies [8, 9, 22] but we were relatively stringent in our eligibility criteria (which patients are able to change safely), and more selective as to what brands to include for the financial impact estimation. Obviously the outcomes refer to Dutch respiratory health care, its specific patient population and medication use.

In estimating the environmental impact of MDIs, we considered their full amount of propellants.

We did not subtract unknown quantities of propellants that may remain in the canister after use, as we assumed that sooner or later 100% of these gases will be released into the atmosphere. We did not include other environmental impacts of MDIs nor DPIs, as would be is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint LCAs imply other harmful impacts that eventually should be included in a comparison such as human toxicity, marine eutrophication or fossil depletion. [7] Our study implies that if medically safe and possible, choosing the medicine or device with the least environmental impact is imperative in times of global climate crisis. This is not just about patients' choice, as may be suggested by NICE's patient decision aid.

[23] It could be considered the prescriber's task as well. Therefore it should be integrated in medical guidelines and standards as part of health care quality improvement trajectories much like Mortimer et al.

have elegantly proposed and practiced. [24] This should not affect the established fact that suitable patient training and monitoring of inhalation techniques are a sine qua non for effective inhaler use for all a patients, especially for children. [25, 26] In the Netherlands, general practitioners recently updated their guidelines on the management of asthma and COPD, and included a recommendation to consider the environmental impact of the medicine of choice (see Textbox 2) . In view of the health emergency represented by the climate crisis we recommend that pulmonologists also consider to update national and local guidelines and appreciate the potential benefits of advising green inhalers as the device of choice in new diagnostics of asthma and COPD and the benefits of resetting patients currently using MDIs to DPIs if safe and possible. In 2019 Belgian pulmonologists recommended the use of DPIs to lung patients not just because they can deliver better treatment results for asthma and COPD but also because they are "far less damaging to the environment than traditional propellant driven aerosols." [27] Evidently, the chosen medication should be fitting for the individual patient. It is beyond the scope of this study to include all specific circumstances in which patients cannot use DPIs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint Apart from climate and economic benefits we identified more advantages of replacing MDIs with DPIs as suggested by research and practice (Table 3) . The present study does not discuss implementation questions, or probable (dis-)advantages of both MDIs and DPIs. It is certainly useful to address the preferences and prejudices of patients and professionals and we know that citizens, patients and professionals are increasingly willing to choose eco-friendly alternatives but there is no knowledge on this specific shift from MDIs is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint to DPIs. [28] [29] [30] Next to that, while some practical (dis-)advantages of both MDIs and DPIs are known we recommend explaining these to patients similar to the NICE decision aid as well as to professionals. [23, 31] For example, most MDIs do not have dose-counters. While all DPIs have a counter they do not necessarily prevent using an empty device. Without a dose-counter it may be hard to know how many doses are left in the device. Unknowingly using empty MDIs could lead to avoidable exacerbations or even avoidable hospital admissions. Unknowingly replacing MDIs that still contain medication would incur unnecessary cost. [32] Adherence to inhalation instructions may be an issue when it comes to changing, but this is already an issue e.g., not every patient with an MDI uses the recommended, though bulky, spacer. Also, adherence to inhalation medication therapy should be promoted by repeated inhalation instruction.

[33] Switching without sufficient instruction may result in uncontrolled, exacerbations and increased use of health care services. Uniformity of the devices in case of multiple inhaler use is relevant here. Such questions pertain to responsible implementation, a subject we will address in our follow-up study in the context of Covid-19 recovery plans.

The pharmaceutical industry meanwhile continues to develop and study inhalers with lower climate impacts. And new propellants will enter the market. For patients who are dependent on MDIs, this is meaningful. Given that these developments have not yet entered the market and knowledge of these is still limited, we will not elaborate on this matter. Research should nonetheless include more green metrics into their output and outcome parameters. This would enable meta-analyses and evidence-based climate-responsible innovation in health care.

Large scale replacement of MPIs with DPIs would have a substantial climate impact in respiratory healthcare. In 2020 about 1.4 million patients using MDI and/or DPI, were prescribed over 460 million DDDs. The use of MDIs is more or less equally prevalent among patients with COPD and patients with asthma. Half (50.4%) of the medication has been delivered using MDIs that have a relatively high global warming potential. The percentage of DPI-delivered inhalation medication that can safely be replaced is estimated to be 70%, resulting in an environmental health benefit of 80,388,501 kg.CO2 eq. on average, which equals the carbon dioxide emission of just over 4000 Dutch households. This shift could be achieved with low budgetary risk. In the low-cost scenario it may even lead to a cost reduction of approximately EUR 49.8 million per year in Dutch respiratory health care. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.20.21266571 doi: medRxiv preprint Twitter @hcointox

The Lancet Countdown on health and climate change: from 25 years of inaction to a global transformation for public health

Academies -Science Advisory Council (2019) The imperative of climate action to protect human health in Europe

Health care's climate footprint

The environmental footprint of health care: a global

Exploring the potential role of inhaler prescribing

NHG-richtlijn Astma bij volwassenen

Genees-en hulpmiddelen Informatie Project | Medicines and medical devices Information Project

DBC Informatie Systeem | Diagnosis-Treatment Combination Information system

Sustainability in quality improvement: redefining value

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers

Mastery of pMDI technique, asthma control and quality-of-life of children with asthma: A randomized controlled study comparing two inhaler technique training approaches

Belgian lung specialists recommend environmentally friendly inhalers that produce better treatment results for lung patients

Citizen support for climate action

Environmental Awareness for Patients with COPD Undergoing Pulmonary Rehabilitation: Is It of Added Value?

Views of health professionals on climate change and health: a multinational survey study. Lancet Planet Health

Inhaler competence in asthma: Common errors, barriers to use and recommended solutions

Disadvantages of salbutamol pressurised metered-dose questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

The authors would like to thank the National Health Care Institute for their support in drafting this paper.

All authors meet the required criteria for authorship. PtH contributed to the conception, designed the study, did most of the analysis and interpretation of the data. PvH, IW, JK, PdH, NC, EB, PH helped analyse and interpret the data for health care practice and implementation issues, and revised the manuscript. HCO contributed to the conception, drafted the manuscript and revised it for intellectual content.

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

PtH, PvH, IW, PdH, EB, NC, PdH and HCO, report no competing interests. JK reports personal fees from BENU Pharmacists, BENU Nederland B.V. / Brocacef Groep N.V.

Not required.

Not commissioned; to be externally peer reviewed.

Both databases used for this article are publicly accessible. Commercially sensitive information related to brand names cannot be made available.

All authors meet the required criteria for authorship: substantial contributions to the conception or design of the work; the acquisition, analysis or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version